Literature DB >> 6429277

"On-off" phenomenon in Parkinson's disease: correlation to the concentration of dopa in plasma.

T Eriksson, T Magnusson, A Carlsson, A Linde, A K Granérus.   

Abstract

To investigate the relation between "on-off" fluctuations in symptomatology and bioavailability of dopa in patients with Parkinson's disease, five Parkinsonian patients with pronounced "on-off" symptoms were studied. Continuously during the study the degree of disability in the patients was registered. Every one hour, and in addition, whenever there was a change from "on" to "off" or vice versa, a blood sample was collected for dopa determination. Since dopa is transported from plasma into the brain by a saturable carrier for which it has to compete with endogenous large neutral amino acids (LNAA), the concentrations of these competitors were measured too. In four of the patients there were considerable oscillations in the plasma dopa concentration during the day; in one of these patients the highest value was as much as 12 times higher than the lowest value. These dramatic fluctuations in the absolute concentration of dopa in plasma had a major influence on the relative dopa concentrations (calculated as the ratio dopa/sum of LNAA) as the fluctuations in the concentrations of LNAA in plasma were much less pronounced. Consequently, the absolute and the relative concentrations of dopa in plasma were highly parallelled. In four of the five patients "on"-periods began within one hour after a peak in the concentration of dopa in plasma and in the fifth patient five out of seven "on"-periods were preceded by a rise in plasma dopa concentration within the same time interval. From the present data it could be concluded that the "on-off" phenomenon in Parkinson's disease, at least partly, is due to oscillations in the concentration of dopa in plasma. A reduction in the variations of the concentration of dopa in plasma seems to be necessary to overcome the "on-off" problem. The introduction of a slow release preparation of dopa is therefore urgently warranted. The concentration of LNAA in plasma must, however, also be considered in this context.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6429277     DOI: 10.1007/bf01250010

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  18 in total

1.  Variation of levodopa metabolism with gastrointestinal absorption site.

Authors:  M Sandler; C R Ruthven; B L Goodwin; K R Hunter; G M Stern
Journal:  Lancet       Date:  1974-02-16       Impact factor: 79.321

2.  Sustained-release levodopa.

Authors:  A C Woods; G A Glaubiger; T N Chase
Journal:  Lancet       Date:  1973-06-16       Impact factor: 79.321

3.  Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease.

Authors:  R D Sweet; F H McDowell
Journal:  Neurology       Date:  1974-10       Impact factor: 9.910

4.  Variability of L-dopa absorption in man.

Authors:  D N Wade; P T Mearrick; D J Birkett; J Morris
Journal:  Aust N Z J Med       Date:  1974-04

5.  "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.

Authors:  S Fahn
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

6.  DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA.

Authors:  T A Hare; B L Beasley; R A Chambers; D H Boehme; W H Vogel
Journal:  Clin Chim Acta       Date:  1973-05-18       Impact factor: 3.786

Review 7.  Role of precursor availability in control of monoamine biosynthesis in brain.

Authors:  J D Fernstrom
Journal:  Physiol Rev       Date:  1983-04       Impact factor: 37.312

8.  On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients.

Authors:  I Shoulson; G A Glaubiger; T N Chase
Journal:  Neurology       Date:  1975-12       Impact factor: 9.910

9.  Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?

Authors:  A Carlsson
Journal:  J Neural Transm Suppl       Date:  1983

10.  Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa.

Authors:  N Quinn; C D Marsden; J D Parkes
Journal:  Lancet       Date:  1982-08-21       Impact factor: 79.321

View more
  10 in total

1.  Sustained-release of levodopa: single dose study of a new formulation.

Authors:  M Gerlach; W Kuhn; T Müller; P Klotz; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Madopar HBS and the decompensated phase of Parkinson disease.

Authors:  T Caraceni; N Nordera; E Lamperti; A Lorizio
Journal:  Ital J Neurol Sci       Date:  1989-08

Review 3.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

4.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

5.  Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa.

Authors:  J G Nutt; W R Woodward; J H Carter; T L Trotman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-04       Impact factor: 10.154

6.  Cerebellar stimulation prevents Levodopa-induced dyskinesia in mice and normalizes activity in a motor network.

Authors:  Jimena Laura Frontera; Elodie Perrin; Adèle Combes; Bérénice Coutant; Thibault Tarpin; Fabien Menardy; Caroline Mailhes-Hamon; Sylvie Perez; Bertrand Degos; Laurent Venance; Clément Léna; Daniela Popa
Journal:  Nat Commun       Date:  2022-06-09       Impact factor: 17.694

7.  Parkinsonian abnormality of foot strike: a phenomenon of ageing and/or one responsive to levodopa therapy?

Authors:  J R Hughes; S G Bowes; A L Leeman; C J O'Neill; A A Deshmukh; P W Nicholson; S M Dobbs; R J Dobbs
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

Review 8.  Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease.

Authors:  Luxi Wang; Nian Xiong; Jinsha Huang; Shiyi Guo; Ling Liu; Chao Han; Guoxin Zhang; Haiyang Jiang; Kai Ma; Yun Xia; Xiaoyun Xu; Jie Li; Jing Y Liu; Tao Wang
Journal:  Front Aging Neurosci       Date:  2017-06-28       Impact factor: 5.750

Review 9.  Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients.

Authors:  Teresia M Osborn; Penelope J Hallett; James M Schumacher; Ole Isacson
Journal:  Front Cell Neurosci       Date:  2020-04-03       Impact factor: 5.505

10.  Deep Brain Stimulation and Treatment Outcomes of Young- and Late-Onset (≤55 Years) Parkinson's Disease: A Population-Based Study.

Authors:  Emanuele Camerucci; Cole D Stang; Pierpaolo Turcano; Philip W Tipton; James H Bower; Anhar Hassan; Bryan T Klassen; Rodolfo Savica
Journal:  Front Neurol       Date:  2021-12-10       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.